NTx 428 regimen (Trillium Therapeutics)

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameNTx 428 regimen (Trillium Therapeutics)
Drug Alias NameErythropoeitin + prolactinErythropoeitin + hCGhCG + erythropoeitinProlactin + erythropoeitinNTx-428
ClassificationBiologics
Mechanisms of ActionCell differentiation stimulantsStem cells stimulantsBeta-nerve growth factor stimulants
TargetsBeta-nerve growth factor
Therapy Area/IndicationsBrain Injuries, Traumatic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesTrillium Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Of Calgary
Active IndicationsN/A
Inactive IndicationsBrain Injuries, Traumatic

Other Information

ATC CodeN/A
Related LinksN/A